2020
A smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin
Kondo J, Huh WJ, Franklin JL, Heinrich MC, Rubin BP, Coffey RJ. A smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin. The Journal Of Pathology 2020, 252: 441-450. PMID: 32944951, PMCID: PMC7802691, DOI: 10.1002/path.5552.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsSmooth muscle cellsICC hyperplasiaMuscle cellsTyrosine kinase inhibitor imatinibFrequent driver eventsCommon mesenchymal tumorsSmooth muscle cell progenitorsDevelopment of GISTsKinase inhibitor imatinibLoss of Trp53ICC-DMPGut motilityStromal tumorsMesenchymal tumorsMouse modelInhibitor imatinibInterstitial cellsMutant BRAFBRAF expressionTumorsBRAFHyperplasiaCell progenitorsDriver events
2016
Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, Meyer C, Lennon AM, Johnston FM, Ahuja N. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? Journal Of Surgical Oncology 2016, 115: 351-357. PMID: 27885685, DOI: 10.1002/jso.24514.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsCause-specific mortalityGIST patientsDiagnosis of GISTCases of GISTLarge nation-wide studyGastric gastrointestinal stromal tumorsGastric GIST patientsCommon mesenchymal tumorsFive-year survivalApproval of imatinibNation-wide studySEER databaseStromal tumorsMesenchymal tumorsGastrointestinal tractAge 50PatientsSurvival analysisSimilar outcomesTumorsPrevious reportsFrequent useOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply